Archives: Search / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012
Jun 1, 2021 Lannett Company, Inc. (NYSE: LCI) today announced the U.S. Food and Drug Administration (FDA) has accepted the Abbreviated New Drug Application (ANDA) for Fluticasone Propionate and Salmeterol... More |
May 5, 2021 Q3 Business and Financial Highlights: Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 third quarter ended March 31, 2021. "In recent months, we have significantly advanced a number of strategic... More |
Apr 28, 2021 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 third quarter on Wednesday, May 5, 2021, after the market closes. Lannett management... More |
Apr 22, 2021 --Transaction Proceeds Used to Retire Company's Term Loan B Due 2022-- Lannett Company, Inc. (NYSE: LCI) today announced the closing of the $350 million aggregate principal amount of 7.750% senior secured notes due 2026 (the "Notes") in a private placement to... More |
Apr 9, 2021 Lannett Company, Inc. (NYSE: LCI) (the "Company" or "Lannett") today announced the pricing of the $350 million aggregate principal amount of 7.75% senior secured notes due 2026 (the "Notes") in a... More |
Apr 6, 2021 Lannett Company, Inc. (NYSE: LCI) (the "Company") today announced that it intends to offer, subject to market conditions and other factors, $350 million aggregate principal amount of senior... More |
Apr 1, 2021 Lannett Company, Inc. (NYSE: LCI) today announced the submission of an Abbreviated New Drug Application (ANDA) for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg... More |
Mar 10, 2021 --FDA Provides Feedback on Pivotal Trial Protocol and Statistical Analysis Plan-- Lannett Company, Inc. (NYSE: LCI) today announced that it recently received feedback from the U.S. Food and Drug Administration (FDA) regarding biosimilar insulin glargine, a product the company... More |
Feb 9, 2021 --Lannett and HEC to Co-develop Insulin Aspart; Lannett Granted Exclusive US Commercialization Rights-- Lannett Company, Inc. (NYSE: LCI) today announced that it has added a new co-development agreement for biosimilar insulin aspart with its strategic alliance partners within the HEC Group of... More |
Feb 8, 2021 Lannett Company, Inc. (NYSE: LCI) today announced that it has begun marketing Chlorpromazine Hydrochloride Tablets, USP, 10 mg, 25 mg, 50 mg, 100 mg and 200 mg. The company recently received... More |